ZyVersa Therapeutics (ZVSA) highlights newly published animal model data demonstrating that inflammasome inhibition attenuates ...

Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.

announced promising results from a study on its Inflammasome ASC Inhibitor IC 100, which may serve as an effective treatment for obesity-associated cardiomyopathy (OAC), a condition characterized ...

In the United States, obesity is estimated to cause between 280,000 and 374,000 deaths each year and more than $170 billion ...

high blood pressure and obesity. But living in highly stressed neighborhoods explained only part of the reason for the higher rates of peripartum cardiomyopathy in Black women. We found that even ...